Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research. Its lead product is ESKATA, a hydrogen peroxide topical solution that has completed Phase III clinical trials for the treatment of raised seborrheic keratosis (SK), a common non-malignant skin tumor. The company is also developing A-101, a hydrogen peroxide topical solution, which has completed Phase II clinical trials for the treatment of common warts. In addition, it is developing JAK inhibitors, including ATI-501, which is in Phase II clinical trials for the oral treatment of alopecia totalis and alopecia universalis; and ATI-502 that is in Phase II clinical trials for the topical treatment of patchy autoimmune dermatologic condition, vitiligo, androgenetic alopecia, and loss of eyebrow hair. Further, the company provides contract research services, such as laboratory services under contract research arrangements to pharmaceutical and biotech companies; and discovers and develops kinase inhibitors to treat inflammatory and immunological disorders and cancer. It has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. Aclaris Therapeutics, Inc. was founded in 2012 and is headquartered in Wayne, Pennsylvania.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACRS
Previous Symbol
CUSIPN/A
Phone484-324-7933
Debt
Debt-to-Equity RatioN/A
Current Ratio6.53
Quick Ratio6.48
Price-To-Earnings
Trailing P/E Ratio-2.80
Forward P/E Ratio-1.75
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.68 million
Price / Sales170.58
Cash FlowN/A
Price / Cash FlowN/A
Book Value$7.31 per share
Price / Book0.96
Profitability
EPS (Most Recent Fiscal Year)($2.50)
Net Income$-68,520,000.00
Net Margins-1,578.24%
Return on Equity-63.74%
Return on Assets-56.49%
Miscellaneous
Employees96
Outstanding Shares40,940,000
Market Cap$299.24 million
OptionableOptionable
Aclaris Therapeutics (NASDAQ:ACRS) Frequently Asked Questions
What is Aclaris Therapeutics' stock symbol?
Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."
How were Aclaris Therapeutics' earnings last quarter?
Aclaris Therapeutics Inc (NASDAQ:ACRS) announced its earnings results on Tuesday, November, 6th. The biotechnology company reported ($1.06) EPS for the quarter, beating the Zacks' consensus estimate of ($1.25) by $0.19. The biotechnology company had revenue of $1.63 million for the quarter, compared to analysts' expectations of $1.58 million. Aclaris Therapeutics had a negative net margin of 1,578.24% and a negative return on equity of 63.74%. View Aclaris Therapeutics' Earnings History.
When is Aclaris Therapeutics' next earnings date?
What price target have analysts set for ACRS?
4 equities research analysts have issued 12-month price objectives for Aclaris Therapeutics' stock. Their forecasts range from $34.00 to $53.00. On average, they expect Aclaris Therapeutics' stock price to reach $47.25 in the next twelve months. This suggests a possible upside of 575.0% from the stock's current price. View Analyst Price Targets for Aclaris Therapeutics.
What is the consensus analysts' recommendation for Aclaris Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aclaris Therapeutics.
What are Wall Street analysts saying about Aclaris Therapeutics stock?
Here are some recent quotes from research analysts about Aclaris Therapeutics stock:
- 1. According to Zacks Investment Research, "Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. " (12/6/2018)
- 2. Cantor Fitzgerald analysts commented, ": Post a solid quarter of execution, and ahead of what we expect to be important positive catalysts for the company, we are reiterating our OW rating and 12-month PT of $50 for ACRS shares. We expect upward earnings revisions to levels not yet reflected in sell-side consensus expectations to drive the stock higher. This could come from the commercialization and/or advancement of each of ACRS’s key assets. These are: 1) An acceleration in the uptake of Eskata for SK and Rhofade for rosacea, 2) A-101 Phase 3 data for warts, 3) ATI-501 and ATI-502 data releases throughout 2018 and 2019, and, 4) The advancement of ATI-450." (11/6/2018)
Has Aclaris Therapeutics been receiving favorable news coverage?
News stories about ACRS stock have been trending negative this week, according to InfoTrie. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aclaris Therapeutics earned a news sentiment score of -2.4 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the next several days.
Who are some of Aclaris Therapeutics' key competitors?
Some companies that are related to Aclaris Therapeutics include G1 Therapeutics (GTHX), Insmed (INSM), Clovis Oncology (CLVS), Kiniksa Pharmaceuticals (KNSA), Apellis Pharmaceuticals (APLS), Uniqure (QURE), Deciphera Pharmaceuticals (DCPH), Retrophin (RTRX), Rhythm Pharmaceuticals (RYTM), Amphastar Pharmaceuticals (AMPH), TherapeuticsMD (TXMD), Homology Medicines (FIXX), Puma Biotechnology (PBYI), Crinetics Pharmaceuticals (CRNX) and Athenex (ATNX).
Who are Aclaris Therapeutics' key executives?
Aclaris Therapeutics' management team includes the folowing people:
- Dr. Neal Walker D.O., Co-Founder, CEO, Pres & Director (Age 48)
- Mr. Christopher V. Powala, Co-Founder and Chief Regulatory & Devel. Officer (Age 59)
- Dr. Stuart D. Shanler, Co-Founder & Chief Scientific Officer (Age 57)
- Mr. Frank Ruffo, Co-Founder & CFO (Age 52)
- Ms. Kamil Ali-Jackson J.D., Co-Founder, Chief Legal Officer, Chief Compliance Officer & Sec. (Age 59)
Who are Aclaris Therapeutics' major shareholders?
Aclaris Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (9.36%), FMR LLC (9.35%), BlackRock Inc. (8.13%), Vanguard Group Inc. (2.90%), Vanguard Group Inc (2.90%) and Citadel Advisors LLC (2.85%). Company insiders that own Aclaris Therapeutics stock include Anand Mehra, Andrew Kenneth William Powell, Andrew N Schiff, Frank Ruffo, Kamil Ali-Jackson, Neal Walker, Stephen A Tullman and Ventures Fund Vii LP Vivo. View Institutional Ownership Trends for Aclaris Therapeutics.
Which institutional investors are selling Aclaris Therapeutics stock?
ACRS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Marshall Wace North America L.P., Redmile Group LLC, Franklin Resources Inc., Blair William & Co. IL, C WorldWide Group Holding A S, TIAA CREF Investment Management LLC and Credit Suisse AG. View Insider Buying and Selling for Aclaris Therapeutics.
Which institutional investors are buying Aclaris Therapeutics stock?
ACRS stock was acquired by a variety of institutional investors in the last quarter, including Man Group plc, Morgan Stanley, Dimensional Fund Advisors LP, BlackRock Inc., Russell Investments Group Ltd., Jefferies Group LLC, Rosenblum Silverman Sutton S F Inc. CA and Citadel Advisors LLC. Company insiders that have bought Aclaris Therapeutics stock in the last two years include Anand Mehra, Andrew Kenneth William Powell, Andrew N Schiff, Frank Ruffo, Neal Walker and Stephen A Tullman. View Insider Buying and Selling for Aclaris Therapeutics.
How do I buy shares of Aclaris Therapeutics?
Shares of ACRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aclaris Therapeutics' stock price today?
One share of ACRS stock can currently be purchased for approximately $7.00.
How big of a company is Aclaris Therapeutics?
Aclaris Therapeutics has a market capitalization of $299.24 million and generates $1.68 million in revenue each year. The biotechnology company earns $-68,520,000.00 in net income (profit) each year or ($2.50) on an earnings per share basis. Aclaris Therapeutics employs 96 workers across the globe.
What is Aclaris Therapeutics' official website?
How can I contact Aclaris Therapeutics?
Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company can be reached via phone at 484-324-7933 or via email at [email protected]
MarketBeat Community Rating for Aclaris Therapeutics (NASDAQ ACRS)
MarketBeat's community ratings are surveys of what our community members think about Aclaris Therapeutics and other stocks. Vote "Outperform" if you believe ACRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
